Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of CU-20401 for Submental Fat Accumulation
NCT06194188Phase 2Completed
- Sponsor
- Cutia Therapeutics
- Start
- Dec 2023
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of CU-20401 in submental lipohypertrophy (3 arms), sponsored by Cutia Therapeutics. Primary endpoint: Change in both Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) score and Patient-Reported Submental Fat Rating Scale (PR-SMFRS) score at Day 29. Started Dec 2023; status: completed.
02
Drugs
CU-20401
03
Conditions
submental lipohypertrophy
Beyond the preview
Go deeper on NCT06194188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06194188.